Scribe Therapeutics closes IPO of 9,867,000 shares at $15.00 each, including full over-allotment option
AI مارکیٹ کا خلاصہ
Scribe Therapeutics (Nasdaq: SCTX) closed an upsized IPO and a concurrent private placement to Sanofi, raising about $155.5M gross. This is a company-specific biotech financing event that can support SCTX's clinical programs but has limited read-through for broader equity indices, macro assets, or crypto. Any near-term market effect is likely confined to stock-level flows and biotech risk appetite rather than cross-asset repricing.
اثر کی سطح
● لو
متاثرہ اثاثے
NCCOGOLD2USD/USDT-0.26%
AI تجزیاتی سمجھ · NCCOGOLD2USD/USDTAI تجزیاتی سمجھ
● Neutral
ابھی ٹریڈ کریں
⚠️ AI سے تیار کردہ تجزیاتی سمجھ خبروں کے مواد پر مبنی ہے اور صرف معلوماتی مقاصد کے لیے فراہم کی گئی ہے۔ یہ سرمایہ کاری کا مشورہ نہیں ہے اور نہ ہی BingX کے خیالات کی نمائندگی کرتی ہے۔ سرمایہ کاری میں رسک شامل ہے۔ براہ کرم ذمہ داری سے ٹریڈ کریں۔
Scribe Therapeutics (Nasdaq: SCTX) said it closed its initial public offering on July 24, 2026, selling 9,867,000 shares at $15.00 per share, including the full exercise of the underwriters’ over-allotment option. The company said aggregate gross proceeds, including a concurrent private placement, were approximately $155.51 million before underwriting discounts and commissions. It also said it sold 500,000 shares to Sanofi in a concurrent private placement at the IPO price. Scribe describes itself as a clinical-stage biotechnology company developing in vivo CRISPR-based genetic medicines, with lead candidate STX-1150 designed to epigenetically silence PCSK9.
